Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The German Federal Ministry of Education and Research (BMBF) has granted EUR0.9m to Scil Technology to explore the therapeutic potential of repellent proteins for the treatment of rheumatoid arthritis (RA).
Subscribe to our email newsletter
Scil Technology, a company engaged in drug development, formulation and analytics, is a wholly owned subsidiary of BioNet Holding.
Scil Technology CEO Christian Nafe said the grant will enable them to explore an innovative, causal treatment for a debilitating, chronic disease with a huge unmet medical need.
"We have long-standing experience with the controlled, sustained release of therapeutically active proteins for regenerative purposes, and we will now apply our know-how to optimize the product profile," Nafe said.